Release Date: 25 September 2024
Gastrointestinal (GI) cancers, particularly gastric and pancreatic cancers, pose significant therapeutic challenges due to their aggressive nature and often late-stage diagnosis. However, this complexity also creates a su...
Release Date: 25 September 2024
Breast cancer remains one of the most prevalent cancers globally, making it a leading indication for the development of bispecific antibody-drug conjugates (BsADCs). The complexity of breast cancer biology, along with the...
Release Date: 20 September 2024
ESG 401 is an innovative anti-TROP2 antibody-drug conjugate (ADC) developed by Shanghai Escugen Biotechnology in collaboration with Levena Biopharma, a subsidiary of Sorrento Therapeutics. This ADC is designed to target s...
Release Date: 20 September 2024
Trastuzumab envedotin (DP303c) represents a significant advancement in targeted cancer therapy as an innovative antibody-drug conjugate (ADC) designed to treat a variety of HER2-expressing tumors. Developed by CSPC ZhongQ...
Release Date: 20 September 2024
Developed by ImaginAb, 89Zr crefmirlimab berdoxam, branded as CD8 ImmunoPET;, is an innovative imaging agent designed for the visualization of the immune system, particularly in patients undergoing immunothe...
Release Date: 20 September 2024
CMG901, also known as AZD0901, is an innovative antibody-drug conjugate (ADC) targeting Claudin 18.2, a cell surface protein frequently overexpressed in various solid tumors, particularly gastric cancers. This ADC is comp...
Release Date: 20 September 2024
BAT-8001 is an innovative antibody-drug conjugate (ADC) being developed by Bio-Thera for the treatment of solid tumors, specifically targeting TROP2, a protein often overexpressed in various cancers. This ADC features a h...
Release Date: 19 September 2024
IBI343 is a promising antibody-drug conjugate (ADC) developed by Innovent Biologics, specifically targeting Claudin 18.2, a tight junction protein expressed on various solid tumors, particularly in gastric cancer and panc...
Release Date: 19 September 2024
Trastuzumab mafodotin, also known as IKS014 or LCB14, is a novel antibody-drug conjugate (ADC) developed by LegoChem Biosciences in collaboration with Fosun Pharma and Iksuda Therapeutics. This promising therapy targets H...
Release Date: 19 September 2024
JSKN-003 is an innovative bispecific antibody-drug conjugate (ADC) developed by Alphamab Oncology, targeting HER2-expressing solid tumors. Leveraging a proprietary glycan-specific conjugation platform, JSKN-003 represents...
Release Date: 19 September 2024
Trastuzumab rezetecan (SHR A1811) represents a potential breakthrough in targeted cancer therapy, emerging as a first-in-class antibody-drug conjugate (ADC) specifically directed against the HER2 receptor. Developed by Jiangsu HengRui Medicine, this ...
Release Date: 19 September 2024
Lutetium Lu 177 rosopatamab tetraxetan (177Lu-TLX591) is an innovative radio antibody-drug conjugate (rADC) being developed by Telix Pharmaceuticals, specifically targeting prostate-specific membrane antigen (PSMA). This ...
Release Date: 19 September 2024
9MW2821 is an innovative anti-nectin-4 antibody-drug conjugate (ADC) developed by Mabwell Therapeutics, representing a promising new option in cancer treatment. Targeting the cell surface adhesion molecule and tumor-assoc...
Release Date: 18 September 2024
In the recent years, the development of gamma delta (andgamma;anddelta;) T cell-based immunotherapy represents an innovative approach in cancer treatment that is swiftly augmenting domain due to its plausibility to treat ...
Release Date: 18 September 2024
Initially identified as a negative regulator of T cell activation, VISTA, also known as PD-1H (Programmed Cell Death 1 Homolog), has emerged as a promising therapeutic target in cancer immunotherapy due to its complex rol...